No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy

被引:58
作者
Bschor, T. [1 ,2 ]
Baethge, C. [3 ]
机构
[1] Jewish Hosp Berlin, Dept Psychiat & Psychotherapy, D-13347 Berlin, Germany
[2] Tech Univ Dresden, Univ Hosp, Dept Psychiat, Dresden, Germany
[3] Univ Cologne, Sch Med, Dept Psychiat & Psychotherapy, Cologne, Germany
关键词
antidepressant; changing; depression; switching; treatment-resistant depression; STAR-ASTERISK-D; TREATMENT-RESISTANT DEPRESSION; RANDOMIZED CONTROLLED TRIALS; FAILED MEDICATION TREATMENTS; MAJOR DEPRESSION; OLANZAPINE/FLUOXETINE COMBINATION; AUGMENTATION; NONRESPONDERS; VENLAFAXINE; DISORDERS;
D O I
10.1111/j.1600-0447.2009.01458.x
中图分类号
R749 [精神病学];
学科分类号
100204 [神经病学];
摘要
Objective: Switching antidepressants is a common strategy for managing treatment-resistant depressed patients. However, no systematic reviews have been conducted to date. Method: We systematically searched MEDLINE/EMBASE/Cochrane Central Register of Controlled Trials and additional sources. We included double-blind studies of patients with depressive symptomatology who were not responding to initial antidepressant monotherapy and were subsequently randomized to another antidepressant or to continue the same antidepressant. Results were pooled for meta-analysis of response + remission rates using a fixed-effects model. Results: A total of three studies were included. Switching to another antidepressant was not superior to continuing the initial antidepressant in any of these studies. Our meta-analysis showed no significant advantages to either strategy and no significant heterogeneity of results [OR for response rates: 0.85 (95% CI: 0.55-1.30) favoring continuing]. Conclusion: There is a discrepancy between the published evidence and the frequent decision to switch antidepressants, indicating an urgent need for more controlled studies. Pending such studies we recommend that physicians rely on more thoroughly evaluated strategies.
引用
收藏
页码:174 / 179
页数:6
相关论文
共 36 条
[1]
[Anonymous], PREVENTION TREATMENT
[2]
[Anonymous], LITHIUM NEUROPSYCHIA
[3]
World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care [J].
Bauer, Michael ;
Bschor, Tom ;
Pfennig, Andrea ;
Whybrow, Peter C. ;
Angst, Jules ;
Versiani, Marcio ;
Moeller, Hans-Juergen .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02) :67-104
[4]
Bauer Michael, 2002, World J Biol Psychiatry, V3, P5, DOI 10.3109/15622970209150599
[5]
Bech P., 1986, Assessment of depression, P259
[6]
AN INVENTORY FOR MEASURING DEPRESSION [J].
BECK, AT ;
ERBAUGH, J ;
WARD, CH ;
MOCK, J ;
MENDELSOHN, M .
ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&
[7]
Efficacy and mechanisms of action of lithium augmentation in refractory major depression [J].
Bschor, Tom ;
Bauer, Michael .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (23) :2985-2992
[8]
*CANMAT, 2005, CLIN GUID TREATM DEP
[9]
Carney S, 2003, LANCET, V361, P799
[10]
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression [J].
Corya, Sara A. ;
Williamson, Doug ;
Sanger, Todd M. ;
Briggs, Susan D. ;
Case, Michael ;
Tollefson, Gary .
DEPRESSION AND ANXIETY, 2006, 23 (06) :364-372